Long term favourable course of a case of centroblastic-centrocytic non- Hodgkin lymphoma under administration of an extract of mistletoe (Viscum album);Langfristig guter verlauf unter misteltherapie bei einem patienten mir einem zentroblastisch-zentrozytischen non-Hodgkin-lymphom

Deutsche Medizinische Wochenschrift

Volumn 124, Issue 47, 1999, Pages 1414-1418

  Kuehn, J J ^a  

^a Lukas Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; QUALITY OF LIFE; TREATMENT OUTCOME; VISCUM ALBUM;

EID: 0033607571     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024555     Document Type: Article

References (16)

1. Challis, G. B., H. J. Stam: The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 29 (1990), 545-550.
2. Drobyski, W. R., R. Qazi: Spontaneous regression in non-Hodgkin's lymphoma: Clinical and pathogenetic considerations. Amer. J. Hematol. 31 (1989), 138-141.
3. Djulbegovic, B.: Non-Hodgkin's Lymphoma. In: Decision Making in Oncology. Ed. Djulbegovic, B., Sullivan, D.M. (Churchill Livingston Inc., New York 1997), 57-67.
4. Gabius, S., H.-J. Gabius: Vor dem Durchbruch? Münch. Med. Wschr. 140 (1998), 355.
5. Gattiker, H. H., E. Wiltshaw, D. A. Galton: Spontaneous regression in non-Hodgkin's lymphoma. Cancer 45(1980), 2627-2632.
6. Gorter, R. W., M. v. Wely, M. Stoss, U. Wollina: Subcutaneous infiltrates induced by injection of mistletoe extracts (Iscador®). Am. J. Ther. 5 (3) (1998), 181-187.
7. Hagenah, W., I. Dörges, E. Gafumbegete, T. Wagner: Subcutane manifestationen eines zentrozytischen Non-Hodgkin-Lymphoms an injektionsstellen eines mistelpräparates. Dtsch. Med. Wschr. 123 (1998), 1001-1004
8. Hajto, T., K. Hostanska, M. Fornalski, A. Kirsch: Antitumorale aktivität des immunmodulatorisch wirkenden betagalaktosidspe-zifischen mistellektins bei der klinischen anwendung von mistel- extrakten (Iscador®). Dtsch. Z. Onkol. 23 (1991), 1-6.
9. Hajto, T., K. Hostanska, K. Frei, Ch. Rordorf, H.-J. Gabius: Increased secretion of Tumor Necrosis Factor α, Interleukin-1 and Interleukin-6 by human mononuclear cells exposed to β-Galactosid-specific lectin from clinical applied mistletoe extract. Cancer Res. 50 (1990), 3322-3326.
10. Hiddemann, W.: Low-grade malignant non-Hodgkin lymphomas-current status and trends in therapy. Ther. Umsch. 53 (2) (1996), 123-130.
11. Katz, A., L.M. Sholman, A. Porgador, M. Revel, M. Feldman, L. Eisenbach: Abrogation of B16 melanoma metastases by long-term low dose interleukin-6-therapy. J. Immunother. 13 (1983), 98-109.
12. Kiene, H.: Klinische studien zur misteltherapie karzinomatöser erkrankungen. Eine Übersicht. Therapeutikon 3 (1989), 347-352.
13. Kovacs, E.: Serum levels of IL-12, IL-6 and the production of IFN-gamma, IL-2, IL-4 by peripheral blood mononuclear cells in cancer patients treated with Viscum album extract. J. Cancer Res. Clin. Oncol. 125 (suppl) (1999), 110.
14. Kuehn, J.J., M. Fornalski: Beeinflussung immunkompetenter zellen des peripheren blutes durch viscum album (Iscador®M) bei patientinnen mit mammakarzinom. In: Scheer, R., P. A. Berg, H. Becker (Hrsg.): Mistelextrakte in der Tumortherapie. Stand des Wissens von Forschung und Therapeutischer Anwendung (Hippokrates Verlag, Stuttgart 1996).
15. Porgador, A., E. Tzehoval, A. Katz, E. Vadai, M. Feldmann, L. Eisenbach: Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and conferes immunotherapeutic competence against parenteral metastatic cells. Cancer Res. 52 (1992), 3679-3686.
16. Rappaport, D. C., M. A. Haider, E. Sternthal: Spontaneous regression of intermediate-grade non-Hodgkin's lymphoma. Amer. J. Roentgenol. 172 (1999), 131-133.